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Abstract
Indoleamine 2,3-dioxygenase (IDO), a catabolizing
enzyme of tryptophan, is supposed to play a role in tu-
mor immune escape. Its expression in solid tumors has
not yet been well elucidated: IDO can be expressed by
the tumor cells themselves, or by ill-defined infiltrating
cells, possibly depending on tumor type. We have
investigated IDO expression in 25 cases of non small
cell lung cancer (NSCLC). Using histochemistry and
immunohistochemistry, we found that IDO was ex-
pressed not by tumor cells, but by normal cells infil-
trating the peritumoral stroma. These cells were neither
macrophages nor dendritic cells, and were identified as
eosinophil granulocytes. The amount of IDO-positive
eosinophils varied in different cases, ranging from a
few cells to more than 50 per field at 200 magnifica-
tion. IDO protein in NSCLC was enzymatically active.
Therefore, at least in NSCLC cases displaying a large
amount of these cells in the inflammatory infiltrate,
IDO-positive eosinophils could exert an effective im-
munosuppressive action. On analyzing the 17 patients
with adequate follow-up, a significant relationship
was found between the amount of IDO-positive infiltrate
and overall survival. This finding suggests that the
degree of IDO-positive infiltrate could be a prognostic
marker in NSCLC.
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Introduction
A fundamental question in tumor pathogenesis is why the
immune system is unable to eradicate transformed cells
and why, instead, it becomes tolerant of tumor growth and
metastasis. A possible mechanism is the exploitation, by
the tumor itself, of the mechanisms normally used by the
immune system for preventing self-tissue destruction and
autoimmune diseases. This mechanism is likely to be
involved in downregulating tumor recognition. The occur-
rence of regulatory T cells suppressing immune response in
human tumors has long since been described [1].
However, an entirely new immunosuppressive mechanism
displayed by cells of the myeloid lineage has been described
recently. The enzyme, indoleamine 2,3-dioxygenase (IDO), by
virtue of its catabolization of the essential amino acid trypto-
phan, is endowed with a very powerful immunosuppressive
activity. In pregnant mice, IDO expression in the placenta is
fundamental in preventing the mother’s immune system from
attacking the semiallogenic fetus: inhibition of IDO activity
results in the loss of all allogenic fetuses [2]. It has also been
demonstrated in vitro that IDO expression can be induced in
both macrophages and dendritic cells (DCs) [3–5], which
thereafter acquire the capacity to inhibit cell proliferation. As
result of IDO activity, both T and NK cells reverse their
commitment to cell cycle progression and enter an arrested
state [6,7], with both adaptive and innate immunity being
consequently affected.
It has been suggested that IDO may be a microenvironmen-
tal factor that could play a role in tumor evasion from a T cell–
mediated rejection [8]. Recent evidence suggests that IDO
expression occurs in tumor-draining lymph nodes and in tumor
tissues as well. In the first case, accumulation of IDO-positive
DCs was found in draining nodes from patients with melanoma,
breast, colon, lung, and pancreatic cancers [5]. Less clear,
instead, is the pattern of IDO expression in solid tumor tissues.
Uyttenhove et al. [9] have found IDO expression in tumor cells
in a number of human solid tumors, even though the percent-
age of IDO-positive specimens and IDO-positive tumor cells
varied greatly among the different types of tumors. More
recently, other researchers demonstrated that, in hepatocarci-
noma, IDO expression is restricted to tumor-infiltrating cells,
not to tumor cells [10]. The precise identity of the former cells
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could not be determined, and the cells were considered to
likely be macrophages or DCs.
Non small cell lung cancer (NSCLC) is not only a fre-
quent tumor but also an aggressive one: median survival
is severely reduced in advanced tumors, and the different
chemotherapy and radiotherapy approaches result in poor
enhancement of survival. Tumor-infiltrating lymphocytes in
NSCLC are anergic and do not proliferate, but they can be
expanded after purification and restimulation [11]. For this
reason, NSCLC could be a tumor where IDO-dependent
immune suppression could take place.
Materials and Methods
Patients
Archival formalin-fixed paraffin-embedded tumor samples
were obtained from 21 patients who underwent surgical
therapy at the Surgery Clinic, Policlinico S. Matteo, University
of Pavia (Pavia, Italy), and from patients who underwent sur-
gical therapy at the Thoracic Surgery Department, Ospedale
S. Croce e Carle (Cuneo, Italy). The fresh tumor samples
used for the evaluation of IDO activity, as well as the cryo-
stat section used in immunohistochemistry, were from the
latter center.
All the patients had NSCLC, and none of them had
received therapy before surgery.
Antibodies
A rabbit antihuman IDO antiserum, raised against a
synthetic peptide [12], and a mouse monoclonal antibody
raised against a GST fusion protein from human IDO (both
from Chemicon, Temecula, CA) were used to detect IDO on
paraffin and frozen sections, respectively. To detect macro-
phages and DCs, an anti-CD68 (Dako, Carpinteria, CA)
MoAb and an anti-S100 (Dako) MoAb were used. To detect
NSCLC cells, the AE1/AE3 biclonal antibody (Progen Bio-
technik, Heidelberg, Germany) and the MNF116 (Dako)
MoAb were used. These reagents react with cytokeratins
expressed in NSCLC [13,14]. To detect eosinophils, we used
a mouse MoAb against human Major Basic Protein (MBP;
Cymbus Biotechnology, Hants, UK).
Western Blotting Analysis of Anti-IDO Antiserum Specificity
For protein extraction, cells were lysed for 30 minutes on
ice in RIPA buffer [10 mM Tris, pH 7.5, 150 mM NaCl, 1%
sodium deoxycholate, 1% Nonidet NP-40, 01% sodium
dodecyl sulfate (SDS), 1 mM EDTA, 10 mM KCl, 20 mg/ml
leupeptin, PMSF, and aprotinin]. Protein concentration was
determined using the protein assay reagent (Bio-Rad, Her-
cules, CA) according to the manufacturer’s instructions.
Equal amounts of proteins (25 mg) were fractionated on a
10% SDS polyacrylamide minigel and transferred to nitro-
cellulose filters (Hybond-C; Amersham Biosciences, Little
Chalfont, UK). After staining with Ponceau Red, blots were
saturated overnight in 5% dried milk in TTBS (20 mM Tris,
pH 7.5, 150 mM NaCl, and 0.1% Tween 20). The primary
antibody, a rabbit anti-IDO, was diluted 1:1500 in blocking
buffer. As a secondary antibody, we used a horseradish
peroxidase (HRP)–conjugated antirabbit IgG (Amersham
Biosciences). The ECLWestern blotting method (Amersham
Biosciences) was used for detection. As a control, we used
purified rabbit IDO, obtained as previously described [6].
Immunohistochemistry and Histochemistry
Sections of formalin-fixed paraffin-embedded tumor sam-
ples were stained with the rabbit anti-IDO as follows. Slides
were hydrated through a graded series of ethanol and treated
for 10 minutes at room temperature with 0.5 mg/ml proteinase
K in PBS, as recommended by Chemicon. When required,
endogenous peroxidases were blocked with the peroxidase
block from Dako. Slides were then incubated for 30 minutes
with the rabbit anti-IDO antibody (1:300) in PBS containing
0.05% Tween 20 and 10% normal goat serum. Secondary
antibody was either a HRP-conjugated or an alkaline phos-
phatase (AP)–conjugated antirabbit (EnVision+ System;
Dako), revealedwith AEC (Dako) or Fast Blue (Sigma-Aldrich,
St. Louis, MO), respectively. The latter staining was done in
the presence of Levamisole to block endogenous phospha-
tases. Counterstaining was performed with hematoxylin.
The same protocol was used for immunocytochemistry
on activated macrophages or purified eosinophils. Air-dried
smears were fixed for 2 minutes with 10% formalin, digested
for 5 minutes with proteinase K, and processed as above.
In the case of double staining, the rabbit anti-IDO was
developed with the AEC system described above, then a
second reaction with a mouse antibody (either anticyto-
keratins, anti-S100, or anti-CD68) was performed and re-
vealed with Fast Blue.
In order to verify the specificity of the rabbit antiserum,
we also used an anti-IDO mouse monoclonal on frozen
sections. In this case, sections were fixed for 10 minutes in
cold methanol/acetone (1:1), and stained with the mouse
anti-IDO diluted 1:300 in PBS containing 0.05% Tween
and 10% normal goat serum. Secondary antibody was a
biotin-conjugated antimouse (BioSpA, Milan, Italy), revealed
with AP-conjugated streptavidin (BioSpa) and Fast Red
(LabVision Corporation, Fremont, CA). The same section
was then destained and stained with the MoAb anti-MBP,
revealed with HRP-conjugated streptavidin (BioSpA) and
DAB substrate (LabVision).
The specificity of the immunoreactions was confirmed by
the negative results obtained on adjacent sections by replac-
ing the primary antibody with rabbit or mouse serum.
Peroxidase-positive cells were identified by a histochem-
istry reaction with diaminobenzidine (DAB). Slides, either un-
stained or previously stained with IDO and Fast Blue, were
incubated 20 for minutes at room temperature with DAB, a per-
oxidase substrate that stains peroxisomes brownish red [15].
To identify eosinophils by histochemistry, the slides stained
with IDO were first photographed in specific fields by recording
the microscope coordinates. Afterward, slides were stained with
a standard hematoxylin–eosin stain, a standardMayGrunwald-
Giemsa stain, or Luna’s stain [16]. The latter technique pro-
duces a distinctive red stain and is specific for eosinophils
because it stains only eosinophil granules, Charcott-Leyden
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crystals, and erythrocytes. The previously photographed cells
were then identified through the coordinates and rephoto-
graphed. Images were taken with an Olympus (Nagano, Japan)
C3030 zoom digital camera attached to an Olympus BX51
microscope, with Olympus Camedia Master software.
In order to evaluate IDO-positive infiltrate, each sample
was stained for IDO, then seven fields at200 magnification
were randomly chosen by each of two investigators (S.A. and
G.F.), and IDO-positive cells were counted.
Separation of Cells from Peripheral Blood
To obtain eosinophils, heparinized venous blood was
obtained (after informed consent) from healthy individuals
with eosinophil counts in the upper normal range. A standard
two-step separation, dextran sedimentation followed by
Fycoll, was performed and contaminant erythrocytes were
removed by osmotic lysis. Eosinophils were then purified by
removing neutrophils with CD16 MicroBeads (Miltenyi Bio-
tech, Bergisch Gladbach, Germany) by following exactly the
manufacturer’s instructions.
To obtain neutrophils and macrophages, heparinized
venous blood was obtained (after informed consent) from
healthy volunteers.
To obtain IDO-positive macrophages, PBMCs were iso-
lated by centrifugation on a discontinuous density gradient of
Fycoll-Hypaque (Biochrom KG, Berlin, Germany). Afterward,
monocytes were enriched from adherent PBMCs by means
of immunomagnetic beads (IO Beads; Immunotech-Coulter,
Marseille, France), precisely following the manufacturer’s
instructions. MCSF (Vinci-Biochem, Florence, Italy) was
then added at a concentration of 200 U/ml, and cells were
grown for 5 days. IFN-g (100 U/ml) was then added and, after
48 hours, cells were collected for Western blot analysis.
To obtain neutrophils, a standard two-step separation
(dextran and Fycoll) was performed, followed by osmotic
lysis of contaminant erythrocytes.
Purity of the enriched populations was checked by
Luna’s staining for eosinophils, by flow cytometry analysis
of CD14 membrane expression for monocytes, and by May
Grunwald-Giemsa staining for neutrophils. Only samples
above 95% purity were taken into account.
Separation of Cells from Tumor Tissue
At the time of surgery a specimen of neoplastic tissue was
collected. The procedure for selecting these samples has
been previously described [17]. Samples were checked by
the anatomopathologist. Tissue samples were then pro-
cessed as previously described [18]. Briefly, after removal
of necrotic areas, tissues were dissociated by sterile me-
chanical dissection, and then incubated in tissue culture
containing 500 U/ml collagenase and 300 U/ml hyaluroni-
dase. After stirring for 2 hours, the suspension was filtered
through a wire grid. Cells were then separated on a Percoll
discontinuous gradient with densities of 1.090, 1.085, 1.080,
1.075, 1.070, and 1.065. Cells on top of each layer and at
the bottom of the 1.090 layer were collected separately.
The amount of eosinophils in the different cell fractions
was evaluated by May Grunwald-Giemsa staining.
Given the marked difference in IDO-positive infiltrate,
evaluation of IDO activity was performed in the three tumor
samples displaying the highest amount of infiltrating eosino-
phils, out of the six that were analyzed.
Enzymatic Assay for IDO Activity
IDO activity was assayed by the colorimetric method [19],
with minor modifications. Briefly, 2  106 cells were dis-
rupted by freezing and thawing, the lysate (250 ml) was
cleared by centrifugation, and an equal amount of 2 IDO
buffer (100 mM PBS, pH 6.5, with 40 mM ascorbate, 20 mM
methylene blue, 200 mg/ml catalase, and 800 mM
L-tryptophan, all reagents from Sigma) was added. After
30 minutes at 37jC, 100 ml of 30% trichloroacetic acid was
added to stop the reaction, and a further incubation for
30 minutes at 52jC was performed. After centrifugation, the
supernatant was mixed with an equal amount of Ehrlich’s
reagent (0.8% p-dimethylaminobenzaldehyde in acetic
acid), the color was allowed to develop for 10 minutes,
and then absorbance was read at 490 nm in a spectro-
photometer. Serial dilutions of L-kynurenine were used
as standards. One unit of IDO activity was defined as
the amount of enzyme producing 1 nmol/hr kynurenine.
The amount of protein in the samples was assayed by the
Bradford method, using the Bio-Rad Protein Assay with BSA
as standard.
Results and Discussion
In order to assess IDO expression, an IDO-specific rabbit
antiserum was used [12]. This antiserum has been raised
against the same synthetic peptide used in Ref. [5]. The
specificity of the antiserum was further checked by West-
ern blot analysis on granulocyte neutrophils, which do not
express IDO, on IFN-g–treated macrophages, which do ex-
press IDO, and on purified IDO from rabbit small intestines.
Figure 1. Evaluation of the specificity of the anti-IDO antiserum. Western blot
analysis was performed on IDO protein, purified from rabbit small intestines as
described in Ref. [6] (lane 1), on monocyte-derived macrophages treated with
IFN-c (lane 2), neutrophil PMNs (lane 3), and PMNs treated with IFN-c (lane 4).
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As shown in Figure 1, the antiserum reacted with macro-
phages but not with neutrophils, and recognized purified
rabbit IDO.
Using this antiserum, we found, in all 25 NSCLC tested,
that IDO-positive cells were scattered within the peritu-
moral stroma, and only rarely within the tumor parenchyma
(Figure 2A). This suggests that IDO expression in these
tumors occurs in inflammatory cells rather than in neoplastic
ones. Indeed, double staining with antibodies reacting with
cytokeratins expressed by NSCLC cells, namely, AE1/AE3
and MNF116 [13,14], did not show colocalization with IDO
(data not shown). Instead, IDO-positive cells were found to
be endowed with peroxisomes, although not all cells with
peroxisomes expressed IDO (Figure 2B), indicating that they
could have a myeloid origin. However, neither the CD68
marker nor the S100 marker showed colocalization with IDO
(data not shown), ruling out the possibility that IDO-positive
cells were DCs or macrophages. In order to better identify
the cell type(s) expressing IDO, IDO-stained NSCLC tissues
were photographed, destained, and restained with different
cytochemical techniques. Restaining with the hematoxylin–
eosin technique indicated that IDO-positive cells had
granules in the cytoplasm (data not shown). This finding
suggested the possibility that these cells could be granulo-
cytes. For this reason, restaining with a standard May
Grunwald-Giemsa method was performed. In fact, the IDO-
positive cells did appear to be granulocytes and frequently
showed a bilobated nucleus; furthermore, the eosino-
philic granules in their cytoplasm indicated that they could
be eosinophil granulocytes (Figure 2C). To check this
Figure 2. Cell expression of IDO protein in NSCLC. (A) IDO-positive cells accumulate in the reactive stroma. Immunohistochemistry was performed on formalin-
fixed paraffin-embedded sections using the anti-IDO antiserum, and staining IDO in blue. Original magnification, 25. (B) IDO-positive cells are endowed with
peroxysomes: IDO was stained in blue and peroxysomes in brown. Original magnification, 250. (C) Morphologic evaluation of IDO-positive cells with May
Grunwald-Giemsa staining. The same sample was stained in blue for IDO (left panel) then destained and restained with May Grunwald-Giemsa (right panel).
Arrows indicate IDO-positive eosinophils, whereas arrowheads indicate IDO-negative eosinophils. Original magnification, 250. (D) Morphologic evaluation of
IDO-positive cells with Luna’s staining. The same sample was stained in red for IDO (left panel) then destained and restained with Luna’s staining, a staining
technique specific for eosinophils (right panel). Original magnification, 500. (E) Colocalization of IDO and MBP. In this case, immunohistochemistry was
performed on cryostat sections using a mouse anti-IDO revealed with Fast Red (left panel). After destaining, the sample was restained for MBP, using a specific
MoAb and DAB substrate (right panel). Original magnification, 500. (F) Peripheral blood eosinophils do not express IDO. Eosinophils purified from peripheral
blood (right panel) and monocyte-derived macrophages treated with IFN-c (left panel) were stained in red for IDO. Original magnification, 100.
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hypothesis, a restaining with Luna’s technique, specific for
eosinophils, was performed. IDO-positive cells were also
positive for Luna’s staining (Figure 2D). In order to corrobo-
rate this finding, a mouse anti-IDO monoclonal antibody was
used on frozen sections, and the slides, stained for IDO,
were then restained with a MoAb reacting with MBP, a
marker specific for eosinophils at all stages of activation.
IDO and MBP colocalized (Figure 2E), enabling us to confirm
that IDO-positive cells were eosinophil granulocytes. No
positivity on tumor cells was detected. The pattern of IDO
expression was therefore identical with both antibodies.
This is the first evidence supplied so far that cells of the
granulocytic lineage can express IDO and potentially exert
an immunosuppressive role. The mechanisms that induce
IDO expression in eosinophils remain to be elucidated, but
macrophages in the same samples do not express IDO,
implying that IDO induction in the two cells follows dif-
ferent pathways.
In order to check whether eosinophils constitutively ex-
press IDO or not, eosinophils from peripheral blood were
checked for IDO expression, using IFN-g–treated macro-
phages as positive control. The latter cells were positive, but
peripheral blood eosinophils did not show any IDO expres-
sion (Figure 2F). This finding indicates that eosinophils do
not constitutively express IDO, but rather IDO expression is
acquired as a result of signals received from the tumoral
environment. In a few cases, such as the one displayed in
Figure 2C, a minor but significant amount of the tumor-
infiltrating eosinophils does not express IDO, substantiating
the finding that IDO expression is induced.
It has to be noted that both the large majority of IDO-
positive eosinophils and all of the immune system cells
potentially endowed with antitumor cytolytic activity are lo-
cated in the peritumoral stroma. In this area, the IDO-positive
eosinophils are, in fact, in close contact with tumor-infiltrating
lymphocytes, as it can be seen in Figure 2C; thus, the enzyme
could exert its immunosuppressive activity at its best.
However, this event can occur only if the enzyme is
active. In order to investigate whether or not IDO is enzy-
matically active, cell fractions of different density were iso-
lated from NSCLC tissue, and IDO activity was assayed in
each. IDO activity was predominantly found in the two cell
fractions with a density between 1.065 and 1.070, and with a
density between 1.070 and 1.075 (Figure 3). This finding
indicates that the enzyme in IDO-positive cells is active, and
has the potential to exert its immunosuppressive activity.
Furthermore, the relationship between IDO activity and the
percentage of eosinophils in the different cell fractions cor-
roborates our conclusion that IDO-positive cells in NSCLC
are indeed eosinophils. Although we did not succeed in dem-
onstrating a direct immunosuppressive activity of NSCLC-
infiltrating eosinophils on T-cell proliferation, due to the great
difficulty in isolating the former cells, the very existence of an
enzymatically active IDO strongly supports the hypothesis of
an IDO-mediated immune suppression.
The occurrence of non-neoplastic cells expressing IDO
within the tumor was recently described by Ishio et al. [10] in
human hepatocellular carcinoma. However, they were not
able to identify the cells responsible for IDO expression and
referred to them as tumor-infiltrating cells, which were likely
to be macrophages or DCs. However, Uyttenhove et al. [9]
found IDO expression by tumor cells in a number of human
solid tumors. However, in both hepatocarcinomas and
NSCLC, the proportion of IDO-positive tumor cells was very
low, and positivity in the latter was weak. Furthermore, they
also found non-neoplastic, albeit unidentified, IDO-positive
cells at the periphery of many tumors.
It is possible that in tumors such as prostatic, pancreatic,
or colorectal carcinomas, IDO is expressed mainly by tumor
cells, whereas in other tumors such as NSCLC or hepato-
carcinomas, IDO is expressed mainly by tumor-infiltrating
inflammatory cells. More generally, different mechanisms at
different levels contribute to IDO expression in tumors: IDO
can be expressed, even concomitantly, in the tumor and
draining lymph nodes, by tumor cells, tumor-associated
eosinophils, DCs, and macrophages. This fact seems to
indicate that IDO expression can confer a growth advan-
tage to tumors, at least for those tumors where an immune-
mediated rejection could take place, such as NSCLC. In
these cases, effective IDO-mediated immune suppression
could foster tumor growth. Because tumor-infiltrating eosi-
nophils are solely responsible for the occurrence of an
IDO-dependent immunosuppression in NSCLC, tumor pro-
gression could be accelerated in those cases displaying a
large amount of these cells in the inflammatory infiltrate.
In this regard, it has to be noted that the amount of IDO-
positive eosinophils greatly changes from one case to an-
other. In Figure 4A, the frequency of IDO-positive cells in the
Figure 3. IDO activity and amount of eosinophils in the cell fractions isolated
by density from NSCLC. Cell suspensions were obtained from fresh tumor
samples by mechanical dissection and enzymatic digestion. Seven cell
subpopulations, having different densities, were obtained by separation on a
Percoll discontinuous gradient. Each subpopulation was assayed for IDO
activity (U/mg protein; black columns) and percentage of eosinophils (white
columns). A single representative experiment, out of the three that were
performed, gives similar results.
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25 different samples examined is displayed. The amount of
IDO-positive cells ranges from a few scattered cells to more
than 50 cells per field at 200 magnification.
In order to investigate whether or not a relationship
between IDO-positive infiltration and disease outcome could
be found in NSCLC, patients with complete staging and
adequate follow-up were selected. In these 17 patients, the
amount of IDO-positive infiltrate was compared to survival,
and an inverse correlation was found (Figure 4B; Spearman
correlation coefficient: r = 0.65, P = .005). The patients
were then divided into two groups: the group of patients
surviving less than 3 years, and the group of patients surviv-
ing more than 3 years. A summary of the distribution of clini-
cal data and of IDO-positive infiltrate between the two groups
is provided in Table 1. A marked difference in IDO-positive
infiltrates between the two groups was found. We are well
aware of the uneven distribution between the two groups of
parameters, such as stage and grading, that affect survival.
We cannot conclude whether a large IDO-positive infiltrate is
the cause or the result of a poor prognosis. Further studies
and a much larger cohort of patients are required to confirm
the prognostic role of IDO-positive infiltrate.
It has to be noted that immunotherapy has been taken into
account in NSCLC [11,20–22]. If the physio-pathologic
relevance of IDO-dependent immune suppression is con-
firmed, adoptive immunotherapy should be reconsidered.
Either a way to overcome this suppression should be pur-
sued, or adoptive immunotherapy should be restricted to
patients displaying low levels of IDO-positive infiltrate.
The relevance of IDO expression in eosinophils should
also be investigated in certain nontumoral diseases, such
as asthma, where an eosinophil infiltrate plays a patho-
physiological role. Indeed, we do not know whether the
conditions inducing IDO expression in eosinophils infiltrat-
ing the inflammatory peritumoral stroma are peculiar to the
tumor environment, or can be found in other inflamma-
tory sites.
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Table 1. Relationship between IDO Expression and Clinical Data.
Survival
<3 Years (n = 9)
Survival
>3 Years (n = 8)
Age (mean ± 1 SD; years) 32–70 (53.7 ± 12.4) 35–67 (54.2 ± 12.6)
Sex (M/F) 8/1 7/1
Histotype
























IDO-positive cells per fieldy





*All patients died due to systemic relapse.
yThe amount of IDO-positive cells was evaluated as indicated in the Materials
and Methods section.
Figure 4. Amount of IDO-positive infiltrate in the different patients, and its
relationship with survival. (A) The frequency of IDO-positive cells differs in the
different NSCLC. Each sample was stained for IDO, seven fields at 200
magnification were randomly chosen by each of two investigators, and then
IDO-positive cells were counted; the mean value is shown. Each dot rep-
resents a single patient. (B) For each patient, the amount of IDO-positive
infiltrate was related to the overall survival.
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